Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction: The PULSE-MI Randomized Clinical Trial.

ABSTRACT:

Importance

In patients with ST-segment elevation myocardial infarction (STEMI), acute inflammation is related to the extent of myocardial damage and may increase infarct size. Thus, administration of pulse-dose glucocorticoid in the very early phase of infarction may reduce infarct size.

Objective

To determine the cardioprotective effect of prehospital pulse-dose glucocorticoid in patients with STEMI.

Design, setting, and participants

This was a 1:1 investigator-initiated, blinded, placebo-controlled, randomized clinical trial conducted between November 14, 2022, and October 17, 2023, with last follow-up on January 17, 2024. Patients 18 years and older with less than 12 hours of acute chest pain and STEMI were included in the prehospital setting throughout the Region

SUBMITTER: Madsen JM 

PROVIDER: S-EPMC11365011 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature